Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi Therapeutics (MGX) Cash & Equivalents (2023 - 2025)

Metagenomi (MGX) has disclosed Cash & Equivalents for 3 consecutive years, with $41.7 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 52.35% to $41.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41.7 million through Dec 2025, up 52.35% year-over-year, with the annual reading at $41.7 million for FY2025, 52.35% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $41.7 million at Metagenomi, up from $32.8 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $140.6 million in Q4 2023, with the low at $25.1 million in Q3 2024.
  • Average Cash & Equivalents over 3 years is $61.4 million, with a median of $46.7 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents crashed 80.52% in 2024, then surged 52.35% in 2025.
  • Over 3 years, Cash & Equivalents stood at $140.6 million in 2023, then plummeted by 80.52% to $27.4 million in 2024, then soared by 52.35% to $41.7 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $41.7 million, $32.8 million, and $26.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.